New Combination Treatment Approved for Non-Small Cell Lung Cancer
December 7, 2018
The Food and Drug Administration (FDA) approved atezolizumab (TECENTRIQ®), an immunotherapy drug, in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations.This is the first four drug combination treatment approved for lung cancer.Click here to learn more.